Integral Health Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Integral Health Asset Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-425,000	Closed	-$17.2M	–	109
2025 Q4	$17.2M	Sell	425,000 -525,000	-55%	-$12.1M	0.85%	42
2025 Q3	$7.13M	Buy	950,000 +250,000	+36%	+$1.6M	0.48%	62
2025 Q2	$2.61M	Hold	700,000	–	–	0.24%	68
2025 Q1	$1.93M	Buy	700,000 +250,000	+56%	+$1.02M	0.21%	74
2024 Q4	$2.49M	Buy	450,000 +150,000	+50%	+$1.02M	0.21%	73
2024 Q3	$2.5M	Buy	+300,000	New	+$2.47M	0.28%	57
2023 Q3	–	Sell	-180,000	Closed	-$1.57M	–	93
2023 Q2	$1.57M	Buy	180,000 +80,000	+80%	+$932K	0.2%	72
2023 Q1	$1.18M	Buy	+100,000	New	+$956K	0.24%	68

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Integral Health Asset Management's TERN Position: Q1 2026 in Review

Integral Health Asset Management sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 425,000 shares — an estimated $17.2M sold.

Integral Health Asset Management first reported a position in TERN in Q1 2023 and held it in 8 quarters. The position peaked at $17.2M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Integral Health Asset Management reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Integral Health Asset Management sold 425,000 Terns Pharmaceuticals shares in Q1 2026, an estimated $17.2M.
Integral Health Asset Management first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 8 quarters.
Integral Health Asset Management's Terns Pharmaceuticals position peaked at $17.2M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.